Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

264.92
+1.410.53%
Post-market: 265.050.1300+0.05%19:47 EDT
Volume:417.85K
Turnover:110.05M
Market Cap:17.54B
PE:20.44
High:265.50
Open:265.00
Low:260.00
Close:263.52
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.74
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:10.57
PE(LYR):-59.97

Loading ...

Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved

Dow Jones
·
2 hours ago

Ascendis Pharma to regain rights to TransCon technology-based products

TIPRANKS
·
2 hours ago

Ascendis Pharma announces $400M share repurchase plan

TIPRANKS
·
2 hours ago

Ascendis Pharma a/S - to Regain Exclusive Rights to Transcon Technology in Metabolic and Cardiovascular Diseases

THOMSON REUTERS
·
2 hours ago

Press Release: Ascendis Announces Planned $400 Million Share Repurchase Program

Dow Jones
·
3 hours ago

Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570

Reuters
·
Sep 10

Ascendis Pharma announces data from reACHin Trial

TIPRANKS
·
Sep 10

Ascendis Pharma Director Lars Holtug Disposes of 236 Shares Worth $62,337.59

Reuters
·
Sep 04

Ascendis Pharma is Maintained at Outperform by Oppenheimer

Dow Jones
·
Sep 03

Ascendis Pharma a/S : Oppenheimer Raises Target Price to $312 from $304

THOMSON REUTERS
·
Sep 02

Oppenheimer Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Sep 02

Ascendis Pharma Price Target Maintained with a $327.00/Share by Wedbush

Dow Jones
·
Sep 01

H.C. Wainwright trims Ascendis target, says litigation overhang removed

TIPRANKS
·
Aug 31

Ascendis Pharma a/S : H.c. Wainwright Cuts Target Price to $344 from $345

THOMSON REUTERS
·
Aug 31

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

MT Newswires Live
·
Aug 31

Movement Alert|Ascendis Pharma A/S Rises 5.92% in Regular Trading, Global Patent Settlement Reached with BioMarin Over Yuviwel

Market Focus
·
Aug 31

Ascendis Pharma price target lowered to $330 from $333 at Jefferies

TIPRANKS
·
Aug 31

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Aug 31

Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)

THOMSON REUTERS
·
Aug 31

Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31